Dr. Wenseng “Wendy” Pan, partner in Goodwin’s Technology & Life Sciences group, focuses on mergers and acquisitions, technology-based transactions, strategic partnerships and financing transactions, especially in the life sciences and technology industries and in cross-border settings. She leads Goodwin’s life sciences practice in Asia.
Dr. Pan has advised private equity firms in leveraged buy-outs and has represented financial institutions, technology, media and telecoms (TMT), biopharmaceutical, manufacturing, publishing, electronics companies and retail chains in stock and/or cash acquisitions, mergers, tender offers and going-private transactions. She has advised on mergers and acquisitions transactions with an aggregate value over US$10 billion. Dr. Pan also advises on company formation, corporate governance, private and public financings.
Dr. Pan has advised life sciences companies and technology companies in structuring and negotiating complex strategic transactions and other commercial arrangements. Her practice covers product and technology licensing, strategic partnerships and joint venture formations and research, product development and commercialization collaborations as well as mergers and acquisitions and private investments. She has deep experience in representing licensors as well as licensees, involving a broad spectrum of technologies. As a former scientist and a registered U.S. patent attorney, she possesses a unique set of skills for counseling her clients on intellectual property related issues.
Her deep legal experiences, coupled with her unparalleled understanding about the business and technologies and her pragmatic approach, have made her a trusted advisor and go-to person in the U.S.-China life sciences communities. According to one of her clients, she “is an incredibly intelligent lawyer who finds solutions for her clients. She is very personable and responsive – very good to deal with. I recommend her highly. She is one of the few lawyers in China on whom I rely, she understands both the Chinese and U.S. markets.” She has been recognized as a “deal broker” by BioWorld Today.
Dr. Pan has been recognized by IFLR1000 as a leading lawyer for M&A. She was also a recipient of the Legal Services Award by China M&A Association. In addition, she is recognized in the 2016 edition of Who’s Who Legal: Life Sciences (Transactional).
She is a member of the Board of Directors of The BayHelix Group, a not-for-profit organization with the mission to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond.
Prior to joining Goodwin, Dr. Pan was a partner at Sidley Austin LLP. She is fluent in Mandarin Chinese and English.